| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT05886049 A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and… |
Primary endpoint(s) modified |
| 2026-06-12 | NCT05886049 A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and… |
Enrollment increased: 28 -> 38 participants |
| 2026-05-30 | NCT07052994 A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab… |
overall status: "Not Yet Recruiting" → "Withdrawn" |
| 2026-05-30 | NCT07052994 A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab… |
critical why stopped: null → "PI requested" |
| 2026-05-30 | NCT07052994 A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab… |
Enrollment reduced: 32 -> 0 participants |
| 2026-05-30 | NCT07052994 A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab… |
date change Primary completion moved earlier: 2032-12-31 -> 2026-05-21 |
| 2026-05-30 | NCT07052994 A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab… |
date change Completion moved earlier: 2034-12-31 -> 2026-05-21 |
| 2026-05-21 | NCT07211958 Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute… |
Trial sites expanded: 14 -> 24 locations |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-09 | NCT07636564 Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute… | Phase 2 | Not Yet Recruiting |
| 2026-05-26 | NCT07605949 Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML | Phase 2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07211958 | Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute… | Acute Myeloid Leukemias | Recruiting |
| Phase 2 | |||
| NCT06229912 | A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With… | Leukemia | Recruiting |
| NCT05761171 | A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With… | Recurrent Acute Leukemia of Ambiguous Lineage | Active, Not Recruiting |
| NCT07563010 | Menin-Inhibitor Targeted Maintenance in AML | Relapsed Adult AML | Not Yet Recruiting |
| NCT07605949 | Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML | Leukemia Acute Myeloid | Not Yet Recruiting |
| NCT07636564 | Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute… | Acute Leukemia of Ambiguous Lineage | Not Yet Recruiting |
| Phase 1/2 | |||
| NCT07356154 | A Study of Revumenib and Mezigdomide in People With Leukemia | Leukemia | Recruiting |
| NCT04065399 | A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene… | Acute Myeloid Leukemia | Recruiting |
| NCT06284486 | A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of… | Acute Myeloid Leukemia | Recruiting |
| NCT05360160 | A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor… | Acute Myeloid Leukemia | Recruiting |
| Phase 1 | |||
| NCT06226571 | A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With… | Acute Myeloid Leukemias | Recruiting |
| NCT06575296 | Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell… | Acute Leukemia | Recruiting |
| NCT06313437 | Revumenib in Combination With 7+3 + Midostaurin in AML | Acute Myeloid Leukemia | Recruiting |
| NCT06177067 | Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients… | Refractory Acute Myeloid Leukemia | Recruiting |
| NCT06222580 | SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute… | Acute Myeloid Leukemia With FLT3/ITD Mutation | Recruiting |
| NCT05886049 | A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and… | Acute Myeloid Leukemia | Recruiting |
| NCT07283640 | A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients… | Blinatumomab | Not Yet Recruiting |